Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/114693
Author(s): Gonçalves, JP
Severo, M
Rocha, C
Jardim, J
Mota, T
Ribeiro, A
Title: Performance of PRISM III and PELOD-2 scores in a pediatric intensive care unit
Issue Date: 2015
Abstract: The study aims were to compare two models (The Pediatric Risk of Mortality III (PRISM III) and Pediatric Logistic Organ Dysfunction (PELOD-2)) for prediction of mortality in a pediatric intensive care unit (PICU) and recalibrate PELOD-2 in a Portuguese population. To achieve the previous goal, a prospective cohort study to evaluate score performance (standardized mortality ratio, discrimination, and calibration) for both models was performed. A total of 556 patients consecutively admitted to our PICU between January 2011 and December 2012 were included in the analysis. The median age was 65 months, with an interquartile range of 1 month to 17 years. The male-to-female ratio was 1.5. The median length of PICU stay was 3 days. The overall predicted number of deaths using PRISM III score was 30.8 patients whereas that by PELOD-2 was 22.1 patients. The observed mortality was 29 patients. The area under the receiver operating characteristics curve for the two models was 0.92 and 0.94, respectively. The Hosmer and Lemeshow goodness-of-fit test showed a good calibration only for PRISM III (PRISM III: χ 2 = 3.820, p = 0.282; PELOD-2: χ 2 = 9.576, p = 0.022). Conclusions: Both scores had good discrimination. PELOD-2 needs recalibration to be a better reliable prediction tool.
Subject: The Pediatric Risk of Mortality III
Pediatric Logistic Organ Dysfunction
URI: http://hdl.handle.net/10216/114693
Source: Eur J Pediatr, vol. 174(10), p. 1305-1310
Document Type: Artigo em Revista Científica Internacional
Rights: openAccess
Appears in Collections:ISPUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
GoncalvesJPSeveroM2015.pdf151.71 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.